Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001193125-25-201410·Camp4 Therapeutics Corp
Schedule 13D ownership disclosure
CAMP4 Therapeutics Corp.
Common Stock, par value $0.0001 per share · CUSIP: 13463J101
Event date: 2025-09-09
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Polaris Management Co. VII, L.L.C.Reported CIK 0001678203
Shares: 3,023,161 · Class: 6.4%
- Polaris Partners VII, L.P.Reported CIK 0001611189
Shares: 2,825,500 · Class: 6.0%
- Polaris Entrepreneurs' Fund VII, L.P.Reported CIK 0001615991
Shares: 197,661 · Class: 0.4%
- Polaris Partners GP X, L.L.C.Reported CIK 0001910575
Shares: 909,090 · Class: 1.9%
- Polaris Partners X, L.P.Reported CIK 0001910577
Shares: 909,090 · Class: 1.9%
- Amir NashatReported CIK 0001575843
Shares: 3,932,251 · Class: 8.4%
- Brian CheeReported CIK 0001295675
Shares: 909,090 · Class: 1.9%
- Amy SchulmanReported CIK 0001438226
Shares: 909,090 · Class: 1.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-25-201410
- Form type
- SCHEDULE 13D/A
- Filer
- Camp4 Therapeutics Corp
- CIK
- CIK 1736730
- Filed
- Sep 11, 2025
- Reporting period
- Sep 09, 2025
- Description
- Schedule 13D beneficial ownership